Evaluation Of Individualized Comprehensive Treatment Efficacy Of IDH1 Gene Detection Combined With External Drug Sensitivity Test For Malignant Brain Gliomas

Objective : To study the correlation between the mutational status of isocitrate dehydrogenase 1(isocitrate dehydrogenase-1,IDH1)and the results of in vitro drug sensitivity test in patients with malignant gliomas and to evaluate the efficacy of the two methods in individual chemotherapy of malignant gliomas.Methods:Sanger sequencing was used to detect the mutation status of IDH1 in 67 patients with malignant glioma diagnosed by pathology after operation,and the drug sensitivity test in vitro was performed by colloidal drop tumor susceptibility assay(CDDST)in fresh samples.Then analyze the relationship between them.Patients were divided into individualized treatment group and imindividualized treatment group according to whether conduct chemotherapy individually and standardly by the result of the drug sensitivity test or not.Results: Among the 67 patients,14 had mutation of IDH1 gene and 53 had not.The drug sensitivity of BCNU,VP-16 and TMZ in mutant-type was higher than that of wildtype IDH1 patients by in vitro.The difference was statistically significant(P < 0.05).The median survival time of IDH1 mutation patients was 30 months and that of IDH1 wild type patients was 14 months.The difference was statistically significant(P < 0.05).The median survival time of individualized treatment patients was 22 months and that of imindividualized treatment group was 14 months.The difference was statistically significant(P < 0.05).The median survival time of IDH1 mutation combined with individualized treatment subgroup was 32 months,which was significantly longer than that of other subgroups.The difference was statistically significant(P < 0.05).Conclusion:The combination of IDH1 gene detection and external drug sensitivity test to guide individual comprehensive treatment in patients with malignant brain glioma can obtain better clinical effect.